GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vanda Pharmaceuticals Inc (NAS:VNDA) » Definitions » Financial Strength
中文

Vanda Pharmaceuticals (Vanda Pharmaceuticals) Financial Strength : 8 (As of Dec. 2023)


View and export this data going back to 2006. Start your Free Trial

What is Vanda Pharmaceuticals Financial Strength?

Vanda Pharmaceuticals has the Financial Strength Rank of 8. It shows strong financial strength and is unlikely to fall into distressed situations.

Good Sign:

Vanda Pharmaceuticals Inc shows strong financial strength.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.

GuruFocus does not calculate Vanda Pharmaceuticals's interest coverage with the available data. Vanda Pharmaceuticals's debt to revenue ratio for the quarter that ended in Dec. 2023 was 0.05. As of today, Vanda Pharmaceuticals's Altman Z-Score is 2.18.


Competitive Comparison of Vanda Pharmaceuticals's Financial Strength

For the Biotechnology subindustry, Vanda Pharmaceuticals's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vanda Pharmaceuticals's Financial Strength Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vanda Pharmaceuticals's Financial Strength distribution charts can be found below:

* The bar in red indicates where Vanda Pharmaceuticals's Financial Strength falls into.



Vanda Pharmaceuticals Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

Vanda Pharmaceuticals's Interest Expense for the months ended in Dec. 2023 was $0.0 Mil. Its Operating Income for the months ended in Dec. 2023 was $-7.1 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $7.0 Mil.

Vanda Pharmaceuticals's Interest Coverage for the quarter that ended in Dec. 2023 is

GuruFocus does not calculate Vanda Pharmaceuticals's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Vanda Pharmaceuticals Inc has enough cash to cover all of its debt. Its financial situation is stable.

2. Debt to revenue ratio. The lower, the better.

Vanda Pharmaceuticals's Debt to Revenue Ratio for the quarter that ended in Dec. 2023 is

Debt to Revenue Ratio=Total Debt (Q: Dec. 2023 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(2.398 + 7.006) / 181.084
=0.05

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

Vanda Pharmaceuticals has a Z-score of 2.18, indicating it is in Grey Zones. This implies that Vanda Pharmaceuticals is in some kind of financial stress. If it is below 1.81, the company may faces bankrupcy risk.

Warning Sign:

Altman Z-score of 2.18 is in the grey area. This implies that the company is under some kind of financial stress. If it is below 1.8, the company may face bankruptcy risk.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vanda Pharmaceuticals  (NAS:VNDA) Financial Strength Explanation

The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.

Vanda Pharmaceuticals has the Financial Strength Rank of 8. It shows strong financial strength and is unlikely to fall into distressed situations.


Vanda Pharmaceuticals Financial Strength Related Terms

Thank you for viewing the detailed overview of Vanda Pharmaceuticals's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


Vanda Pharmaceuticals (Vanda Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
2200 Pennsylvania Avenue NW, Suite 300 E, Washington, DC, USA, 20037
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises two products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS) and Fanapt for the treatment of schizophrenia. Its other products include VHX-896 and ASO Molecules. The majority of revenue is derived from HETLIOZ product sales.
Executives
Joakim Wijkstrom officer: SVP, Chief Marketing Officer 2200 PENNSYLVANIA AVE NW, SUITE 300E, WASHINGTON, DC DC 20037
Stephen Ray Mitchell director C/O VANDA PHARMACEUTICALS INC., 2200 PENNSYLVANIA AVE., SUITE 300E, WASHINGTON DC 20037
Kevin Patrick Moran officer: VP, Acting CFO & Treasurer C/O VANDA PHARMACEUTICALS INC., 2200 PENNSYLVANIA AVENUE, SUITE 300E, WASHINGTON DC 20037
Timothy Williams officer: SVP & General Counsel C/O VANDA PHARMACEUTICALS INC., 2200 PENNSYLVANIA AVENUE NW, SUITE 300E, WASHINGTON DC 20037
Tage Honore director C/O VANDA PHARMACEUTICALS INC., 2200 PENNSYLVANIA AVENUE, SUITE 300E, WASHINGTON DC 20037
Mihael Hristos Polymeropoulos director, officer: Chief Executive Officer 9605 MEDICAL CENTER DRIVE SUITE 300, ROCKVILLE MD 20850
Gunther Birznieks officer: SVP, Business Development 2200 PENNSYLVANIA AVE NW, SUITE 300E, WASHINGTON DC 20037
Thomas Watkins director 1221 GULF SHORE BLVD N #303, NAPLES FL 34102
Aranthan Ii Jones officer: Chief Corp. Affairs Officer 2200 PENNSYLVANIA AVE NW, SUITE 300E, WASHINGTON DC DC 20037
Phaedra Chrousos director 2200 PENNSYLVANIA AVE NW, SUITE 300E, WASHINGTON DC 20037
Richard W Dugan director 20425 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
James Patrick Kelly officer: SVP, CFO, Treasurer & Secretar C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Gian Piero Reverberi officer: SVP, General Manager Europe 2200 PENNSYLVANIA AVENUE, SUITE 300E, WASHINGTON DC 20037
Anne Sempowski Ward director C/O VANDA PHARMACEUTICALS INC., 2200 PENNSYLVANIA AVENUE, SUITE 300E, WASHINGTON DC 20037
Vincent Milano director C/O VIROPHARMA INC, 405 EAGLEVIEW BLVD, EXTON PA 19341